eversyn is a spin-off of the Max Planck Institute Magdeburg - run, founded and supported by current and former Max Planck scientists and business professionals. Their proprietary technology is based on the efficient use of novel biocatalytic cascades. They have designed and engineered these pathways to produce nucleotide sugars by magnitude of orders cheaper than the current production costs. Building on that, they are engineering biocatalysts to produce novel complex human milk oligosaccharides and tailor the glycosylation of therapeutic proteins.